ELCC: Subgroup Analyses Support First-Line Cemiplimab’s Long-term Benefit in NSCLC
Recorded Courses
hosted byProjects In Knowledge Inc. (PIK)
hosted byProjects In Knowledge Inc. (PIK)
attend it anywhere online
category
Medicine, Nursing
Oncology
price
Free
ELCC: Subgroup Analyses Support First-Line Cemiplimab’s Long-term Benefit in NSCLC is organized by Projects In Knowledge Inc. (PIK).
Release Date: Apr 12, 2023
Termination Date: Apr 11, 2024
Learning Objective(s):
• Summarize recent clinical trial findings utilizing immunotherapy for patients with treatment naïve advanced or metastatic NSCLC.
• Understand the relationship between tumor histology and response to PD-L1 checkpoint inhibitor therapy.
Additional details will be posted as soon as information is available.